Changes of Erythrocyte Fatty Acids after Supplementation with Highly Concentrated Docosahexaenoic Acid (DHA) in Pediatric Cystic Fibrosis

We characterized the fatty acid profiles in the erythrocyte membrane of pediatric patients with cystic fibrosis (CF) receiving highly concentrated docosahexaenoic acid (DHA) supplementation (Tridocosahexanoin-AOX ® 70%) at 50 mg/kg/day (n = 11) or matching placebo (n = 11) for 12 months. The mean ag...

Descripción completa

Detalles Bibliográficos
Autores: Ayats-Vidal, Roser|||0000-0002-5245-9847, Bosque, Montserrat|||0000-0001-5426-4034, Cordobilla, Begoña|||0000-0002-0418-9387, Asensio-De la Cruz, Oscar|||0000-0001-9304-3074, García-González, Miguel|||0000-0002-4330-7200, Castro-Marrero, Jesús|||0000-0002-2481-3052, López-Rico, Irene|||0000-0002-5886-7948, Domingo, Joan Carles|||0000-0002-6356-0836
Tipo de recurso: artículo
Fecha de publicación:2023
País:España
Institución:Universitat Autònoma de Barcelona
Repositorio:Dipòsit Digital de Documents de la UAB
Idioma:inglés
OAI Identifier:oai:ddd.uab.cat:290206
Acceso en línea:https://ddd.uab.cat/record/290206
https://dx.doi.org/urn:doi:10.3390/jcm12113704
Access Level:acceso abierto
Palabra clave:Cystic fibrosis
Docosahexaenoic acid
Eicosapentaenoic acid
Fatty acids
Omega-3
Pancreatic insufficiency
Randomized controlled study
Descripción
Sumario:We characterized the fatty acid profiles in the erythrocyte membrane of pediatric patients with cystic fibrosis (CF) receiving highly concentrated docosahexaenoic acid (DHA) supplementation (Tridocosahexanoin-AOX ® 70%) at 50 mg/kg/day (n = 11) or matching placebo (n = 11) for 12 months. The mean age was 11.7 years. The DHA group showed a statistically significant improvement in n-3 polyunsaturated fatty acids (PUFAs), which was observed as early as 6 months and further increased at 12 months. Among the n-3 PUFAs, there was a significant increase in DHA and eicosapentaenoic acid (EPA). Additionally, a statistically significant decrease in n-6 PUFAs was found, primarily due to a decrease in arachidonic acid (AA) levels and elongase 5 activity. However, we did not observe any changes in linoleic acid levels. The long-term administration of DHA over one year was safe and well tolerated. In summary, the administration of a high-rich DHA supplement at a dose of 50 mg/kg/day for one year can correct erythrocyte AA/DHA imbalance and reduce fatty acid inflammatory markers. However, it is important to note that essential fatty acid alterations cannot be fully normalized with this treatment. These data provide timely information of essential fatty acid profile for future comparative research.

Similares en LA Referencia